Brokerages Set Avantor, Inc. (NYSE:AVTR) PT at $25.93

Avantor, Inc. (NYSE:AVTRGet Free Report) has earned an average recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, Marketbeat reports. Four equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $27.21.

A number of equities research analysts have recently issued reports on the stock. Citigroup downgraded shares of Avantor from a “buy” rating to a “neutral” rating and cut their price objective for the company from $30.00 to $23.00 in a research report on Wednesday, July 10th. Barclays boosted their price objective on shares of Avantor from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Monday, July 29th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $31.00 target price on shares of Avantor in a report on Monday, July 29th. TD Cowen upped their target price on shares of Avantor from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 29th. Finally, Evercore ISI dropped their target price on shares of Avantor from $28.00 to $27.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd.

Read Our Latest Stock Analysis on Avantor

Avantor Trading Down 3.4 %

Shares of AVTR stock opened at $25.60 on Monday. Avantor has a 1 year low of $16.63 and a 1 year high of $28.00. The firm has a fifty day moving average price of $22.59 and a 200-day moving average price of $23.81. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05. The company has a market cap of $17.40 billion, a price-to-earnings ratio of 65.64, a PEG ratio of 2.71 and a beta of 1.32.

Insiders Place Their Bets

In other news, insider Christophe Couturier 10,000 shares of the company’s stock in a transaction dated Tuesday, July 30th. The was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Avantor

Several hedge funds have recently made changes to their positions in AVTR. Versant Capital Management Inc raised its position in Avantor by 2,003.6% in the 2nd quarter. Versant Capital Management Inc now owns 1,157 shares of the company’s stock worth $25,000 after purchasing an additional 1,102 shares during the period. Fifth Third Bancorp boosted its stake in shares of Avantor by 125.3% during the fourth quarter. Fifth Third Bancorp now owns 1,248 shares of the company’s stock valued at $28,000 after purchasing an additional 694 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its position in Avantor by 565.5% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 1,331 shares of the company’s stock valued at $30,000 after acquiring an additional 1,131 shares during the last quarter. Blue Trust Inc. boosted its stake in Avantor by 1,830.3% in the second quarter. Blue Trust Inc. now owns 1,467 shares of the company’s stock valued at $31,000 after acquiring an additional 1,391 shares in the last quarter. Finally, Gladius Capital Management LP purchased a new position in Avantor in the fourth quarter worth $42,000. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Avantor Company Profile

(Get Free Report

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Further Reading

Analyst Recommendations for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.